NCT06371261

Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic Fibrosis

Pathogenicity of Species of the Achromobacter Genus in Patients With Cystic Fibrosis: a Prospective Multicentre Exploratory Study of a Cohort in Réunion Island.
Centre Hospitalier Universitaire de la Réunion·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Cystic Fibrosis
Drug/Device/Intervention
Biological analyses
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Centre Hospitalier Universitaire de la Réunion
Location
Saint-Denis,Saint-Pierre, Réunion
Timeline & enrollment
Phase
N/A
Start date
Feb 29, 2024
End date
Mar 01, 2027
Enrollment
35 participants
Primary outcome

Frequency of pulmonary exacerbations according to the species of the Achromobacter genus colonising/infecting cystic fibrosis patients.

Summary

The pathogenicity of Achromobacter bacteria is not yet well established, but studies show a
 decline in respiratory function and an increase in mortality associated with chronic
 colonisation, making it possible to classify the Achromobacter genus as an emerging pathogen
 in cystic fibrosis. It is possible that certain species or clones are more virulent or
 resistant, requiring the adaptation of measures to prevent cross-transmission in the centres
 concerned.
 
 However, until now, the identification of Achromobacter species has involved the use of
 molecular biology techniques that are not routinely applicable in diagnostic laboratories,
 limiting studies and the collection of epidemiological data. Recently, a database using
 MALDI-TOF mass spectrometry has been built for rapid and accurate species identification.
 
 In view of the local epidemiology and the current lack of data, it would be necessary and
 interesting to use this tool to study a cohort of cystic fibrosis patients in Réunion island
 (North and South sites) to see whether one species has a greater clinical impact than another
 (pathogenicity), and/or is more responsible for chronic colonisation.

ICD-10 classifications
Cystic fibrosisCystic fibrosis, unspecifiedCystic fibrosis with other manifestationsCystic fibrosis with pulmonary manifestationsCystic fibrosis with intestinal manifestations
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06371261
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06371261 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre Hospitalier Universitaire de la Réunion and is currently Recruiting. The study focuses on Cystic Fibrosis. Target enrollment is 35 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.